United Therapeutics Corporation (UTH.F)

197.65 +1.55 (+0.79%) As of 08:03AM CET. Market open.

United Therapeutics Corporation

1040 Spring Street
Silver Spring, MD 20910
United States
301 608 9292
https://www.unither.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 985

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.	Founder, Chairman & CEO	3.51M	5.08M	1955
Mr. Michael I. Benkowitz	Pres & COO	1.96M	17.34M	1972
Mr. James C. Edgemond	CFO & Treasurer	1.42M	N/A	1968
Mr. Paul A. Mahon J.D.	Exec. VP, Gen. Counsel & Corp. Sec.	1.67M	12.39M	1964
Mr. Dewey Steadman C.F.A.	Head of Investor Relations	N/A	N/A	N/A
Ms. Holly Hobson	Associate VP of HR	N/A	N/A	N/A
Kevin T. Gray	Sr. VP of Strategic Operations & Logistics	N/A	N/A	N/A
Mr. Patrick Poisson	Exec. VP of Technical Operations	N/A	N/A	1968
Mr. Gil Golden	Sr. VP & Chief Medical Officer	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Corporate Governance

United Therapeutics Corporation’s ISS Governance QualityScore as of March 1, 2023 is 4. The pillar scores are Audit: 4; Board: 5; Shareholder Rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.